Objective
Tuberculosis is a leading killer world-wide, and the proportion of Paediatric tuberculosis is expanding. Although the BCG vaccine triggers specific T and B cell responses in neonates, it only confers protection from severe forms of tuberculosis in the firs t years of life. BCG does not significantly protect adults from pulmonary tuberculosis. There is therefore an urgent need to develop novel vaccines against tuberculosis, which would provide a long lasting protection following neonatal inoculation. One appr oach to this crucial aim is to decipher the mechanisms involved in neonatal immune responses to mycobacteria. For this purpose, we have established a consortium of experts in Genetics, Immunology, Microbiology and Paediatrics, as well as a biotechnology co mpany. Our objective is to dissect the molecular and cellular immune responses in neonates and infants, combining three complementary models, namely mice, humanized mice, and human patients. We will compare the innate and adaptive immune responses, with an emphasis on dendritic cells and T-cells. We will investigate neonatal and adult mice during mycobacterial infection and following inoculation of a novel and promising candidate vaccine, methylated HBHA. In addition, we will investigate such responses usin g mice reconstituted de novo with human lymphoid and myeloid hemopoietic-derived cell lineages, allowing for the first time an experimental dissection of human immunity to mycobacteria. The immune responses of naturally infected humans in the corresponding age groups will also be monitored and compared. Finally, the human molecular basis of hyper-susceptibility to live BCG in rare neonates with disseminated BCG disease will be investigated, in order to discover novel mycobacterial susceptibility genes, whic h will then be tested in the humanized mouse model. The feasibility of this research programme is attested by the high scientific quality and remarkable complementarity of the participants.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences genetics
- medical and health sciences basic medicine immunology
- medical and health sciences clinical medicine pneumology tuberculosis
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
- medical and health sciences clinical medicine paediatrics
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP6-2004-LIFESCIHEALTH-5
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
STOCKHOLM
Sweden
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.